🟢 Moleculin Biotech is trading 5.78% up today in pre-market after new Annamycin data presentations for September meetings

Moleculin Biotech is trading 5.78% up in pre-market at $0.82 after announcing new Annamycin presentations for three September scientific meetings.

• The September 14 announcement covers pancreatic-cancer antitumor activity, tissue concentration, topoisomerase II targeting, and potential immune-mediated activity.
• Shares rose from $0.71 on September 11 to $0.78 on September 14; no reliable volume or additional September 15 announcement was found.
• The release is the clearest identified catalyst; it discloses no financing, earnings surprise, regulatory decision, or partnership.